[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100393802":3},{"organization":4,"outcomesModule":7,"designInfo":46,"detailedDescription":45,"studyPopulation":49,"armGroups":45,"interventions":50,"overallOfficials":45,"centralContacts":54,"locations":60,"responsibleParty":76,"collaborators":45,"id":80,"slug":45,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":45,"enrollmentInfo":89,"targetDuration":92,"studyType":93,"phases":45,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":63,"whyStopped":45,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"European Georges Pompidou Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":45},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of cardio-toxicty","Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic","5 years",[14,17,20,23,26,29,32,36,39,42],{"measure":15,"description":16,"timeFrame":12},"Analysis of cardiotoxicity","Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes.",{"measure":18,"description":19,"timeFrame":12},"Analysis of cardioprotective strategies","Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity.",{"measure":21,"description":22,"timeFrame":12},"Analysis of underlying cardiovacsular profile","Correlation between underlying cardioascular profile and the number of patients with cardiotoxicity.",{"measure":24,"description":25,"timeFrame":12},"Analysis of arrhythmias","Correlation between incident arrhythmias and cancer drugs",{"measure":27,"description":28,"timeFrame":12},"Precision medicine","Correlation between biomarkers with use of artificial intelligence and the number of patients with cardiotoxicity.",{"measure":30,"description":31,"timeFrame":12},"Oncology","Adherence to oncology treatment plan as stated in the multidisciplinary team meeting in patients with cardio-oncology assessment compared to matched patients with no cardio-oncology assessment within our institution; outcomes.",{"measure":33,"description":34,"timeFrame":35},"Cardiovascular outcomes","Assess cardiovascular outcomes (cardiovascular death, admission for heart failure, acute coronary syndrome, stroke).","10 years",{"measure":37,"description":38,"timeFrame":12},"Any advserse event","Correlation between any adverse event, oncology treatment, and outcomes.",{"measure":40,"description":41,"timeFrame":12},"Behaviour","Correlation of any behaviour treatment (exercice, rehabilitation, nutrition consultation) and the number of patents with cardiotoxocity.",{"measure":43,"description":44,"timeFrame":12},"Metabolic","Correlation between oncology treatments, cardiovascular therapies, behaviour therapies and the number of patients with metabolic disorders (diabetes or dyslipidemia).",null,{"allocation":45,"interventionModel":45,"interventionModelDescription":45,"primaryPurpose":45,"observationalModel":47,"timePerspective":48,"maskingInfo":45},"COHORT","PROSPECTIVE","All prosepctive patients seen in the cardio-oncology clinic. Observational data will be collected from the medical records. Outcomes measures according to scheduled follow-up visits for their cardiovascular health.",[51],{"type":6,"name":52,"description":53,"armGroupLabels":45,"otherNames":45},"No interventions are planned","Non applicable",[55],{"name":56,"role":57,"phone":58,"phoneExt":45,"email":59},"Mariana Mirabel, MD, PhD","CONTACT","+33156095636","mariana.mirabel@aphp.fr",[61],{"facility":62,"status":63,"city":64,"state":45,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Assistance Publique Hôpitaux de Paris - Centre Université de Paris","RECRUITING","Paris","75015","France","FR",{"type":69,"coordinates":70},"Point",[71,72],2.3488,48.85341,{"lat":72,"lon":71},[75],{"name":56,"role":57,"phone":58,"phoneExt":45,"email":59},{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"PRINCIPAL_INVESTIGATOR","Mariana Mirabel","MD, PhD, Assosiate Professor","100393802",false,"NCT04407780","Cardio-Oncology Registry","Cardio-Oncologie: étude Pilote évaluant la faisabilité, Utilité Concrète, Interdisciplinaire d'Une Unité Spécialisée","CONFUCIUS","Inclusion Criteria:\n\n* referred to cardio-oncology\n\nExclusion Criteria:\n\n* refusal to participate","ALL","18 Years",{"count":90,"type":91},5000,"ESTIMATED","5 Years","OBSERVATIONAL","Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.\n\nCONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt.\n\nThe objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and\u002For drugs.",[96,97,98,99,100],"Cancer","Cardiac Disease","Metabolic Syndrome","Arrhythmia","Heart Diseases",[102,103,104,105,106,107,108],"cancer","heart","cardiovascular","cardio-oncology","onco-cardiology","phamacology","precision medicine","2020-05-25",{"date":111,"type":112},"2020-05-29","ACTUAL",{"date":114,"type":112},"2017-01-01",{"date":116,"type":91},"2027-06-01",{"name":5,"class":6},1]